

【Therapeutic category】 625 Anti-virus agents

【Non-proprietary name】 Darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving rifampicin, phenobarbital, phenytoin, fosphenytoin, carbamazepine, apalutamide, food containing St. John's Wort, enzalutamide, triazolam, midazolam, pimozide, simvastatin, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, ergometrine, methylergometrine, vardenafil, sildenafil (Revatio), tadalafil (Adcirca), blonanserin, azelnidipine, azelnidipine/olmesartan medoxomil, eplerenone, lurasidone, lomitapide, finerenone, voclosporin, ivabradine, venetoclax (during dose titration phase for relapsed or refractory chronic lymphocytic leukemia [including small lymphocytic lymphoma]), isavuconazonium sulfate, anamorelin hydrochloride, mavacamten, rivaroxaban, and ticagrelor	2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving rifampicin, phenobarbital, phenytoin, fosphenytoin, carbamazepine, apalutamide, food containing St. John's Wort, enzalutamide, <u>ivosidenib, encorafenib, mitotane</u>, triazolam, midazolam, pimozide, simvastatin, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, ergometrine, methylergometrine, vardenafil, sildenafil (Revatio), tadalafil (Adcirca), blonanserin, azelnidipine, azelnidipine/olmesartan medoxomil, eplerenone, lurasidone, lomitapide, finerenone, voclosporin, ivabradine, venetoclax (during dose titration phase for relapsed or refractory chronic lymphocytic leukemia [including small lymphocytic lymphoma]), isavuconazonium sulfate, anamorelin hydrochloride, mavacamten, rivaroxaban, and ticagrelor

10. INTERACTIONS			10. INTERACTIONS		
10.1 Contraindications for Co-administration (Do not co-administer with the following)			10.1 Contraindications for Co-administration (Do not co-administer with the following)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Enzalutamide	The blood concentrations of darunavir and cobicistat may decrease, leading to a reduction in the effect of this drug.	Due to the CYP3A-inducing activity of <u>enzalutamide</u> .	Enzalutamide <u>Ivosidenib</u> <u>Encorafenib</u> <u>Mitotane</u>	The blood concentrations of darunavir and cobicistat may decrease, leading to a reduction in the effect of this drug.	Due to the CYP3A-inducing activity of <u>these drugs</u> .

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.